Cardiff Oncology to Present at the Jefferies London Healthcare Conference

Rhea-AI Summary

Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company, will present at the Jefferies London Healthcare Conference from November 15-17, 2022. The presentation is scheduled for November 15 at 3:55 PM GMT (10:55 AM ET) and will include a corporate presentation followed by a Q&A session. The company focuses on PLK1 inhibition in developing therapies for cancers such as KRAS/NRAS-mutated metastatic colorectal cancer and metastatic pancreatic ductal adenocarcinoma. A replay will be available on their website for 90 days.

SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present and participate in 1x1 investor meetings at the Jefferies London Healthcare Conference, which is taking place in London, UK from November 15 – 17, 2022.

Details of the presentation can be found below.

Jefferies London Healthcare Conference

Date:	Tuesday, November 15, 2022
Time:	3:55 PM GMT / 10:55 AM ET
Format:	Corporate Presentation and Q&A Session
Webcast Link	Here

A replay of the presentation will be available by visiting the "Events" section of the Cardiff Oncology website and will be archived for 90 days.

About Cardiff Oncology, Inc.

Cardiff Oncology is a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers. Our lead asset is onvansertib, a PLK1 inhibitor we are evaluating in combination with standard-of-care (SoC) therapeutics in clinical programs targeting indications such as KRAS/NRAS-mutated metastatic colorectal cancer (mCRC) and metastatic pancreatic ductal adenocarcinoma (mPDAC), as well as in investigator-initiated trials in triple negative breast cancer (TNBC) and small cell lung cancer (SCLC). These programs and our broader development strategy are designed to target tumor vulnerabilities in order to overcome treatment resistance and deliver superior clinical benefit compared to the SoC alone. For more information, please visit https://www.cardiffoncology.com.

Cardiff Oncology Contact:
James Levine
Chief Financial Officer
858-952-7670
jlevine@cardiffoncology.com  

Investor Contact:
Joyce Allaire
LifeSci Advisors
212-915-2569
jallaire@lifesciadvisors.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/cardiff-oncology-to-present-at-the-jefferies-london-healthcare-conference-301671205.html

SOURCE Cardiff Oncology, Inc.

FAQ

When will Cardiff Oncology present at the Jefferies London Healthcare Conference?

Cardiff Oncology will present on November 15, 2022, at 3:55 PM GMT (10:55 AM ET).

What is the focus of Cardiff Oncology's presentation at the Jefferies London Healthcare Conference?

The presentation will cover the company's development of therapies leveraging PLK1 inhibition for various cancers.

Is there a way to watch Cardiff Oncology's presentation after it occurs?

Yes, a replay of the presentation will be available on Cardiff Oncology's website for 90 days.

What are the dates for the Jefferies London Healthcare Conference?

The conference will take place from November 15 to 17, 2022.

What is the stock symbol for Cardiff Oncology?

The stock symbol for Cardiff Oncology is CRDF.